Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Pipamperone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 3/20 | 0.98 |
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 0.98 |
| ▸ | SLC6A4 known ✓ | P31645 | 3/20 | 0.98 |
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 0.98 |
| ▸ | OPRM1 known ✓ | P35372 | 3/20 | 0.98 |
| ▸ | DRD3 known ✓ | P35462 | 3/20 | 0.98 |
| ▸ | SLC6A3 known ✓ | Q01959 | 3/20 | 0.98 |
| ▸ | KCNH2 known ✓ | Q12809 | 3/20 | 0.98 |
| ▸ | DRD1 known ✓ | P21728 | 2/20 | 0.98 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.98 |
| ▸ | DRD2 known ✓ | P14416 | 7/20 | 0.60 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.54 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.54 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.54 |
| ▸ | CHRM3 known ✓ | P20309 | 2/20 | 0.54 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.54 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.54 |
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 0.54 |
| ▸ | HTR2B known ✓ | P41595 | 2/20 | 0.54 |
| ▸ | GHSR known ✓ | Q92847 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pipamperone SCHEMBL8764867 | 1.00 | HTR1A (0.98) | HTR1AADRA2ASLC6A4ADRA1AOPRM1 | |
| Pipamperone SCHEMBL364623 | 1.00 | HTR1A (0.98) | HTR1AADRA2ASLC6A4ADRA1AOPRM1 | |
| Pipamperone SCHEMBL2412 | 0.99 | HTR1A (1.00) | HTR1AADRA2ASLC6A4ADRA1AOPRM1 | |
| Pipamperone SCHEMBL6621425 | 0.99 | HTR1A (1.00) | HTR1AADRA2ASLC6A4ADRA1AOPRM1 | |
| Pipamperone SCHEMBL647930 | 0.98 | HTR1A (0.98) | HTR1AADRA2ASLC6A4ADRA1AOPRM1 | |
| Pipamperone SCHEMBL10533161 | 0.98 | HTR1A (0.98) | HTR1AADRA2ASLC6A4ADRA1AOPRM1 | |
| Pipamperone SCHEMBL14696833 | 0.98 | HTR1A (0.98) | HTR1AADRA2ASLC6A4ADRA1AOPRM1 | |
| Pipamperone SCHEMBL8327319 | 0.97 | HTR1A (0.96) | HTR1AADRA2ASLC6A4ADRA1AOPRM1 | |
| Pipamperone SCHEMBL2552074 | 0.97 | HTR1A (0.96) | HTR1AADRA2ASLC6A4ADRA1AOPRM1 | |
| Pipamperone SCHEMBL21357035 | 0.96 | HTR1A (0.94) | HTR1AADRA2ASLC6A4ADRA1AOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1273301-B1 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON SA (CH) | 2006-09-06 | — | — | EP | claimed |
| EP-1273301-A2 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON S.A. (CH) | 2003-01-08 | — | — | EP | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-12582606-B2 | Tablet and method for producing tablet | SUNSHO PHARMACEUTICAL CO., LTD. (JP) | 2026-03-24 | — | — | US | disclosed |
| US-20240016745-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | TOWA PHARMACEUTICAL CO., LTD. (JP) | 2024-01-18 | — | — | US | disclosed |
| US-20230381168-A1 | ADJUNCTIVE THERAPY FOR DEPRESSION | ANEUROTECH BV (BE) | 2023-11-30 | — | — | US | disclosed |
| EP-4260847-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING SAME | TOWA PHARMACEUTICAL CO., LTD. (JP) | 2023-10-18 | — | — | EP | disclosed |
| CN-110325193-B | Novel medical use of compound III | 勃林格殷格翰国际有限公司 | 2023-05-05 | — | — | CN | disclosed |
| US-20230091682-A1 | COGNITIVE DISORDER PREVENTION AND THERAPY | ANEUROTECH BV (BE) | 2023-03-23 | — | — | US | disclosed |
| EP-4087552-A1 | COGNITIVE DISORDER PREVENTION AND THERAPY | Aneurotech IP BV (BE) | 2022-11-16 | — | — | EP | disclosed |
| US-20220218616-A1 | TABLET AND METHOD FOR PRODUCING TABLET | SUNSHO PHARMACEUTICAL CO., LTD. (JP) | 2022-07-14 | — | — | US | disclosed |
| EP-0665009-B1 | CRYSTALLINE CONDITION DISLOCATING METHOD | NIPPON SHINYAKU CO LTD (JP) | 2000-02-16 | — | — | EP | disclosed |
| US-5830497-A | Medicated plaster containing basic physiologically active agents and/or salts thereof | NITTO DENKO CORPORATION (JP) | 1998-11-03 | — | — | US | disclosed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | disclosed |
| EP-0452837-B1 | Adhesive device for transdermal administration of an active agent | NITTO DENKO CORP (JP) | 1995-08-16 | — | — | EP | disclosed |
| EP-0665009-A1 | CRYSTALLINE CONDITION DISLOCATING METHOD | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1995-08-02 | — | — | EP | disclosed |
| EP-0387751-B1 | Medicated plasters | NITTO DENKO CORP (JP) | 1994-06-08 | — | — | EP | disclosed |
| US-5176916-A | Plaster layer containing a medicinal ingredient, hydrophobic polymer, absorption promoter, water and a hydrophilic polymer | NITTO ELECTRIC INDUSTRIAL CO., LTD. (JP) | 1993-01-05 | — | — | US | disclosed |
| EP-0452837-A2 | Adhesive device for transdermal administration of an active agent | NITTO DENKO CORPORATION (JP) | 1991-10-23 | — | — | EP | disclosed |
| EP-0387751-A2 | Medicated plasters | NITTO DENKO CORPORATION (JP) | 1990-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12582606-B2 | Tablet and method for producing tablet | GRHPR, RCC1, KIT | HTR1A 1430/4885ADRA2A 2229/4885SLC6A4 3595/4885 |
| US-20230091682-A1 | COGNITIVE DISORDER PREVENTION AND THERAPY | HTR2A, HTR1A, HTR2C | HTR1A 2/4885ADRA2A 41/4885SLC6A4 17/4885 |
| US-20230381168-A1 | ADJUNCTIVE THERAPY FOR DEPRESSION | HTR2A, HTR3B, HTR5A | HTR1A 6/4885ADRA2A 23/4885SLC6A4 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.